Xeris Biopharma Holdings
XERS
239 hedge funds and large institutions have $857M invested in Xeris Biopharma Holdings in 2026 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 106 increasing their positions, 65 reducing their positions, and 28 closing their positions.
88% more call options, than puts
Call options by funds: $8.64M | Put options by funds: $4.59M
63% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 65
40% more capital invested
Capital invested by funds: $611M → $857M (+$246M)
25% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 28
1.67% more ownership
Funds ownership: 61.01% → 62.68% (+1.7%)
1% more funds holding
Funds holding: 237 → 239 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.1M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$9.38M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.86M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$5.36M |
| 5 |
Walleye Capital
New York
|
+$3.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$13.6M |
| 2 |
VC
Voss Capital
Houston,
Texas
|
-$8.04M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$7.79M |
| 4 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$6.18M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.24M |
XERS Hedge Fund Activity: Q2 2026 in Review
239 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2026, worth a combined $857M — up 40% from $611M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new XERS positions and 28 closed out — a net gain of 7 holders — while 106 added to existing stakes and 65 trimmed.
The largest buyer was BlackRock, adding an estimated $10.1M. The largest seller was Millennium Management, cutting an estimated $13.6M.
- 239 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2026, up from 237 in Q1 2026.
- Funds reported $857M of Xeris Biopharma Holdings stock for Q2 2026, up 40% quarter-over-quarter.
- 35 funds opened new Xeris Biopharma Holdings positions in Q2 2026 and 28 closed out, a net change of +7 holders.
- The largest Xeris Biopharma Holdings buyer in Q2 2026 was BlackRock, an estimated $10.1M added.
- The largest Xeris Biopharma Holdings seller in Q2 2026 was Millennium Management, an estimated $13.6M sold.
Based on aggregated 13F filings for Q2 2026.